Literature DB >> 26132930

The Emerging Role of Chronic Low-Grade Inflammation in the Pathophysiology of Polycystic Ovary Syndrome.

Soulmaz Shorakae1, Helena Teede1, Barbora de Courten1, Gavin Lambert2, Jacqueline Boyle1, Lisa J Moran1.   

Abstract

Polycystic ovary syndrome (PCOS) has become increasingly common over recent years and is associated with reproductive features as well as cardiometabolic risk factors, including visceral obesity, dyslipidemia and impaired glucose homeostasis, and potentially cardiovascular disease. Emerging evidence suggests that these long-term metabolic effects are linked to a low-grade chronic inflammatory state with the triad of hyperinsulinemia, hyperandrogenism, and low-grade inflammation acting together in a vicious cycle in the pathophysiology of PCOS. Dysregulation of the sympathetic nervous system may also act as an important component, potentially creating a tetrad in the pathophysiology of PCOS. The aim of this review is to examine the role of chronic inflammation and the sympathetic nervous system in the development of obesity and PCOS and review potential therapeutic options to alleviate low-grade inflammation in this setting. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Year:  2015        PMID: 26132930     DOI: 10.1055/s-0035-1556568

Source DB:  PubMed          Journal:  Semin Reprod Med        ISSN: 1526-4564            Impact factor:   1.303


  28 in total

Review 1.  Chronic low-grade inflammation in polycystic ovary syndrome: is there a (patho)-physiological role for interleukin-1?

Authors:  Milica Popovic; Gideon Sartorius; Mirjam Christ-Crain
Journal:  Semin Immunopathol       Date:  2019-05-28       Impact factor: 9.623

2.  Association of IL-1β, IL-1Ra and FABP1 gene polymorphisms with the metabolic features of polycystic ovary syndrome.

Authors:  Nadia Rashid; Aruna Nigam; Pikee Saxena; S K Jain; Saima Wajid
Journal:  Inflamm Res       Date:  2017-04-12       Impact factor: 4.575

3.  Invited Commentary: Women's Reproductive Life Spans and Subsequent Inflammatory Profiles-How to Best Measure Reproductive Life Span and the Need for Baseline Assessments.

Authors:  Karen C Schliep
Journal:  Am J Epidemiol       Date:  2020-07-01       Impact factor: 4.897

4.  The inflammatory markers in polycystic ovary syndrome: association with obesity and IVF outcomes.

Authors:  Y Çakıroğlu; F Vural; B Vural
Journal:  J Endocrinol Invest       Date:  2016-03-15       Impact factor: 4.256

Review 5.  Is cardiorespiratory fitness impaired in PCOS women? A review of the literature.

Authors:  S Donà; E Bacchi; P Moghetti
Journal:  J Endocrinol Invest       Date:  2016-12-27       Impact factor: 4.256

6.  [Research progress on the role of pentraxin 3 in polycystic ovary syndrome].

Authors:  Wei Wu; Jian Xu
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2020-10-25

Review 7.  The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited.

Authors:  Robert L Rosenfield; David A Ehrmann
Journal:  Endocr Rev       Date:  2016-07-26       Impact factor: 19.871

8.  Effects of Melatonin and/or Magnesium Supplementation on Biomarkers of Inflammation and Oxidative Stress in Women with Polycystic Ovary Syndrome: a Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Reihaneh Mousavi; Mohammad Alizadeh; Mohammad Asghari Jafarabadi; Lida Heidari; Roshan Nikbakht; Hossein Babaahmadi Rezaei; Majid Karandish
Journal:  Biol Trace Elem Res       Date:  2021-05-19       Impact factor: 3.738

Review 9.  Beneficial Effects of Green Tea Catechins on Female Reproductive Disorders: A Review.

Authors:  Datu Agasi Mohd Kamal; Norizam Salamt; Siti Sarah Mohamad Zaid; Mohd Helmy Mokhtar
Journal:  Molecules       Date:  2021-05-03       Impact factor: 4.411

10.  Increased Body Mass Index Is Associated With A Nondilutional Reduction in Antimüllerian Hormone.

Authors:  Eleni Greenwood Jaswa; Julie S Rios; Marcelle I Cedars; Nanette F Santoro; Mary Ellen G Pavone; Richard S Legro; Heather G Huddleston
Journal:  J Clin Endocrinol Metab       Date:  2020-10-01       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.